\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\:\\	lower\\ extremities\\ demonstrated\\ multiple\\ pink\\,\\ somewhat\\	translucent\\,\\ 1\\-2\\ cm\\ nodules\\ coalescing\\ into\\ plaques\\ on\\ both\\ ankles\\ and\\ pretibial\\ areas\\.\\ \ \(0\)\
\-\ histopathology\\:\\ sections\\ demonstrated\\ marked\\ mucin\\ deposition\\ in\\ the\\ upper\\ half\\ of\\ the\\ dermis\\ replacing\\ the\\ dermal\\ collagen\\.\ \(0\)\
\-\ lesions\\ have\\ remained\\ stable\\ with\\ no\\ changes\\.\\ topical\\ high\\ potency\\ steroids\\ had\\ no\\ effect\\.\\ he\\ refused\\ a\\ trial\\ of\\ intralesional\\ steroid\\ injections\\.\ \(0\)\
\-\ nodular\\ pretibial\\ myxedema\\ \\(1997\\ uniformed\\ services\\ dermatology\\ seminar\\,\\ case\\#22\\)\\ presented\\ by\\:\\ joseph\\ l\\.\\ wilde\\,\\ cpt\\,\\ mc\\,\\ usa\ \(0\)\
\-\ 63\\ year\\ old\\ white\\ male\\ presented\\ with\\ a\\ six\\ month\\ history\\ of\\ asymptomatic\\ lower\\ extremity\\ nodules\\.\\ past\\ medical\\ history\\ was\\ significant\\ for\\ longstanding\\ diabetes\\ mellitus\\ and\\ hyperthyroidism\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pretibial\\:\\ 0\\.11328643475384585\ \(0\)\
\-\ wilde\\:\\ 0\\.07109289051585886\ \(0\)\
\-\ translucent\\:\\ 0\\.06550299389843994\ \(0\)\
\-\ coalescing\\:\\ 0\\.06550299389843994\ \(0\)\
\-\ potency\\:\\ 0\\.06223311399434184\ \(0\)\
\-\ myxedema\\:\\ 0\\.06223311399434184\ \(0\)\
\-\ nodules\\:\\ 0\\.05713740105488309\ \(0\)\
\-\ cpt\\:\\ 0\\.056643217376922926\ \(0\)\
\-\ refused\\:\\ 0\\.05337333747282482\ \(0\)\
\-\ intralesional\\:\\ 0\\.05105332075950401\ \(0\)\
\-\ mucin\\:\\ 0\\.04925377599084103\ \(0\)\
\-\ replacing\\:\\ 0\\.0487333040461832\ \(0\)\
\-\ usa\\:\\ 0\\.047783440855405916\ \(0\)\
\-\ ankles\\:\\ 0\\.046933759277520214\ \(0\)\
\-\ topical\\:\\ 0\\.046933759277520214\ \(0\)\
\-\ dermal\\:\\ 0\\.04616512879522727\ \(0\)\
\-\ pink\\:\\ 0\\.045806646839010874\ \(0\)\
\-\ sections\\:\\ 0\\.045806646839010874\ \(0\)\
\-\ longstanding\\:\\ 0\\.045806646839010874\ \(0\)\
\-\ hyperthyroidism\\:\\ 0\\.04451356095130782\ \(0\)\
\-\ dermis\\:\\ 0\\.044220273498316885\ \(0\)\
\-\ l\\.\\:\\ 0\\.043663879373422115\ \(0\)\
\-\ trial\\:\\ 0\\.043399445318398\ \(0\)\
\-\ mellitus\\:\\ 0\\.043399445318398\ \(0\)\
\-\ injections\\:\\ 0\\.042895248891129174\ \(0\)\
\-\ demonstrated\\:\\ 0\\.04044225778156399\ \(0\)\
\-\ mc\\:\\ 0\\.040393999469324024\ \(0\)\
\-\ 1\\-2\\:\\ 0\\.03954431789143832\ \(0\)\
\-\ collagen\\:\\ 0\\.039228021817621535\ \(0\)\
\-\ 1997\\:\\ 0\\.038630376880897974\ \(0\)\
\-\ plaques\\:\\ 0\\.038487638355902805\ \(0\)\
\-\ histopathology\\:\\ 0\\.038487638355902805\ \(0\)\
\-\ deposition\\:\\ 0\\.038487638355902805\ \(0\)\
\-\ seminar\\:\\ 0\\.03834738236629096\ \(0\)\
\-\ 63\\:\\ 0\\.038209524032748216\ \(0\)\
\-\ uniformed\\:\\ 0\\.03794068193381602\ \(0\)\
\-\ presented\\:\\ 0\\.03757028443584531\ \(0\)\
\-\ remained\\:\\ 0\\.03755351081134537\ \(0\)\
\-\ services\\:\\ 0\\.03718407906915752\ \(0\)\
\-\ dermatology\\:\\ 0\\.03718407906915752\ \(0\)\
\-\ half\\:\\ 0\\.036382688151309094\ \(0\)\
\-\ steroid\\:\\ 0\\.036382688151309094\ \(0\)\
\-\ joseph\\:\\ 0\\.0356537844297908\ \(0\)\
\-\ diabetes\\:\\ 0\\.03411734633303166\ \(0\)\
\-\ somewhat\\:\\ 0\\.033874176670364825\ \(0\)\
\-\ six\\:\\ 0\\.033874176670364825\ \(0\)\
\-\ steroids\\:\\ 0\\.03241716030943352\ \(0\)\
\-\ lower\\:\\ 0\\.030997775312320362\ \(0\)\
\-\ 22\\:\\ 0\\.030738484822750316\ \(0\)\
\-\ nodular\\:\\ 0\\.028906530702515414\ \(0\)\
\-\ stable\\:\\ 0\\.028404948380983917\ \(0\)\
\-\ \\:\\:\\ 0\\.027345358451387056\ \(0\)\
\-\ extremities\\:\\ 0\\.02702973079791039\ \(0\)\
\-\ \\#\\:\\ 0\\.02702973079791039\ \(0\)\
\-\ marked\\:\\ 0\\.026894189521165377\ \(0\)\
\-\ extremity\\:\\ 0\\.02520289491647127\ \(0\)\
\-\ effect\\:\\ 0\\.024399663331203587\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.023295099983839412\ \(0\)\
\-\ areas\\:\\ 0\\.023188283639081184\ \(0\)\
\-\ white\\:\\ 0\\.022855679134774334\ \(0\)\
\-\ past\\:\\ 0\\.021896769935051887\ \(0\)\
\-\ medical\\:\\ 0\\.021204111290854873\ \(0\)\
\-\ month\\:\\ 0\\.02067431081290814\ \(0\)\
\-\ changes\\:\\ 0\\.019750386905121455\ \(0\)\
\-\ he\\:\\ 0\\.019227317274459834\ \(0\)\
\-\ history\\:\\ 0\\.019035718350114247\ \(0\)\
\-\ high\\:\\ 0\\.018859242428038835\ \(0\)\
\-\ significant\\:\\ 0\\.018531025411727606\ \(0\)\
\-\ cm\\:\\ 0\\.01848351707916924\ \(0\)\
\-\ lesions\\:\\ 0\\.018448068599547965\ \(0\)\
\-\ both\\:\\ 0\\.01759838702166227\ \(0\)\
\-\ physical\\:\\ 0\\.016907300561139017\ \(0\)\
\-\ upper\\:\\ 0\\.016629681494909017\ \(0\)\
\-\ into\\:\\ 0\\.016397793289997634\ \(0\)\
\-\ exam\\:\\ 0\\.015138983386689822\ \(0\)\
\-\ case\\:\\ 0\\.01507664865215541\ \(0\)\
\-\ have\\:\\ 0\\.01492288772875074\ \(0\)\
\-\ had\\:\\ 0\\.014869756606779905\ \(0\)\
\-\ multiple\\:\\ 0\\.014514564544187652\ \(0\)\
\-\ no\\:\\ 0\\.013878131462964547\ \(0\)\
\-\ \\,\\:\\ 0\\.01309887413793326\ \(0\)\
\-\ male\\:\\ 0\\.012461334982963493\ \(0\)\
\-\ by\\:\\ 0\\.01147476534874899\ \(0\)\
\-\ was\\:\\ 0\\.007969980017852313\ \(0\)\
\-\ year\\:\\ 0\\.007710526365104151\ \(0\)\
\-\ old\\:\\ 0\\.007055924168243989\ \(0\)\
\-\ a\\:\\ 0\\.0063967709970742135\ \(0\)\
\-\ for\\:\\ 0\\.0058799044245380246\ \(0\)\
\-\ on\\:\\ 0\\.005837830744882484\ \(0\)\
\-\ \\(\\:\\ 0\\.005825497792289198\ \(0\)\
\-\ \\)\\:\\ 0\\.005754336226720202\ \(0\)\
\-\ in\\:\\ 0\\.003398364759195604\ \(0\)\
\-\ the\\:\\ 0\\.0033447407589586886\ \(0\)\
\-\ and\\:\\ 0\\.002903371060197072\ \(0\)\
\-\ of\\:\\ 0\\.002818640341886817\ \(0\)\
\-\ \\.\\:\\ 0\\.002004006070011483\ \(0\)\
\-\ with\\:\\ 0\\.0018871641304820926\ \(0\)\
